Pralsetinib (Gavreto)

Key Messages

• CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses pralsetinib (Gavreto), 400 mg (four 100 mg oral tablets once daily).
• Indication: For the treatment of adult patients with rearranged during transfection (RET) fusion–positive locally advanced unresectable or metastatic non-small cell lung cancer.